Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07767799

Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice

This a prospective, multicenter, observational pharmacological translational study designed to investigate the biological and imaging correlates of treatment with novel monoclonal antibodies (NMABs) in patients with B-cell non-Hodgkin lymphoma (NHL), enrolled in the observationa FIL_MAB study. Patients enrolled in BIO FIL-MAB are concurrently participating in the FIL-MAB clinical cohort, ensuring that all clinical data-including treatment details, outcomes, and safety-are captured within the main observational study.

Patients will undergo systematic collection of biological specimens including tumor tissue, peripheral blood integrated with advanced imaging data. Biological analyses will encompass molecular, cellular, and immunological assessments, while imaging evaluations will include standardized functional and metabolic imaging techniques. All biological and imaging assessments will be performed as routine clinical visits, without requiring modifications to treatment or additional procedures beyond standard-of-care.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

B-Cell Non-Hodgkin Lymphoma (NHL) Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ematologia - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy

Loading trial locations.

About this study

This a prospective, multicenter, observational pharmacological translational study designed to investigate the biological and imaging correlates of treatment with novel monoclonal antibodies (NMABs) in patients with B-cell non-Hodgkin lymphoma (NHL), enrolled in the observational FIL_MAB study.

All clinical observations, including baseline characteristics, treatment exposure, and follow-up, are collected through the FIL-MAB study database, with a minimum follow-up of 60 months (5 years) from enrollment and correlated with biological findings for translational analysis performed in BIO-FIL_MAB study.

The BIO-FIL_MAB study will employ a structured schedule of biological and imaging assessments to monitor treatment outcomes and gather translational data. The timeline will be aligned with routine clinical practice:

  • Prior to NMAB Treatment
  • During NMAB Therapy (3 months after start of therapy, 9 months after start of therapy, progression/relapse).

This structured schedule ensures a comprehensive evaluation of both clinical and biological treatment effects, aligning with the study's translational objectives.

As an observational translational study primarily intended for descriptive and exploratory analyses, no formal statistical hypothesis testing is planned.

Therefore, the sample size has been determined based on feasibility considerations and the expected availability of patients participating in the parent FIL-MAB clinical cohort, thereby ensuring a robust population for integrated biological, immunological, and imaging analyses in association with clinical outcomes.

Overall, it is anticipated that at least 1000 patients will be consecutively enrolled and followed longitudinally in BIO-FIL_MAB study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years old) are diagnosed with B-cell Non-Hodgkin Lymphoma;
  • Patients enrolled in the FIL_MAB trial (provided by Informed Consent Form (ICF) signature) who are scheduled to receive treatment with novel monoclonal antibodies (NMABs), either as monotherapy or in combination with other therapies;
  • Written informed consent to participate in this study.

Exclusion criteria

  • Patients not enrolled in the FIL_MAB study.
  • Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
  • Uncontrolled and/or active systemic infection (viral, bacterial or fungal), including active ongoing infection from SARSCoV-2;
  • Chronic or acute hepatitis B (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e., HBsAg negative, HBsAb positive and HBcAb negative) or positive HBcAb from previous infection or intravenous immunoglobulins (IVIG) may participate; inactive carriers (HBsAg positive with undetectable HBV- DNA) are eligible. Patients with presence of HCV antibody are eligible only if PCR negative for HCV-RNA;
  • HIV seropositivity;
  • Refusal or inability to provide informed consent.
  • Refusal or inability to provide biological specimens.

Treatment and study plan

WP1 - Task 1 - Liquid analyses

Other

Objectives

  • To investigate the value of circulating tumor DNA (ctDNA)/ Minimal Residual Disease (MRD) status as prognostic biomarker for B-NHL patients treated with commercial bi-specifics antibodies (bsAbs).
  • To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  • To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.

WP1 - Task 2 - Immunological analyses

Other

Objectives

  • evaluate association between levels and subtypes of T cell in PB before and after bsAbs with COs.
  • Analyze expression of PD1, CD25, 41BB/CD137, CTLA4, CD28, and other T cell co-stimulatory molecules, and correlate with COs.
  • Evaluate expansion of NK cells along with their markers of activation, exhaustion, maturation, chemotaxis.
  • evaluate association between T cell exhaustion with treatment failure.
  • evaluate association between T cell exhaustion with previous lines of treatment or other clinical factors such as relapsed time.
  • evaluate association between T cell clusters with the development of cytopenia during treatment.
  • investigate whether immunosenescence (composition and activation status of PBMCs) and inflammaging (soluble mediators) can predict response and clinical outcomes in elderly patients (≧70) undergoing treatment with bsAbs.
  • Immunological characterization of T cell subset by bulk RNAseq before and after bsAbs with COs.

WP1 - Task 3 - Tumor tissue analyses

Other

Objectives

  • Association between specific mutational (Whole Genome Sequencing, WGS) and transcriptomic (Whole Transcriptome Sequencing, WTS) patterns with disease response to bsAbs therapy.
  • To investigate TP53 mutation and del17p as predictive factor of response to bsAbs.
  • Identifying specific relapse patterns, with the hypothesis that alterations in tumor genes facilitating immune evasion are enriched in clones emerging at relapse (i.e., secondary resistance).
  • To characterize intratumoral immune effector cell distribution and to assess T-cell functional fitness and exhaustion states within tumor-draining lymph nodes using Digital Spatial Profiling (DSP).
  • To investigate the association between bsAbs surface target antigens (e.g. CD20) expression level and response to bsAbs.

WP1 - Task 4 - Imaging analyses

Other

Objectives

  • explore how tumor metabolic activity signature predict prognosis and treatment response during bsAbs-approved treatments.
  • explore how tumor heterogeneity activity predicts prognosis and treatment response during bsAbs -approved treatments.
  • explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during bsAbs-approved treatments.
  • explore novel prognostic markers of progression in CT scans and PET scans.
  • apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT scans, aiming to enhance prediction of prognosis and treatment response in patients undergoing bsAbs-approved treatments.
  • develop and validate AI-driven multimodal integration frameworks that combine imaging data with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under bsAbs therapy.

WP1 - Task 5 - Microbiome and metabolomics analyses

Other

Objectives

  • To describe plasma and tissue microbiome composition and metabolomics during bsAbs -approved treatments.
  • To investigate whether microbiome/metabolomics predicts outcomes during bsAbs -approved treatments.
  • To investigate whether microbiome/metabolomics predicts treatment toxicity during bsAbs -approved treatments.

WP2 - Task 1 - Liquid analyses

Other

Objectives

  • To identify and validate biological and molecular biomarkers (i.e. ctDNA/MRD) that predict patient outcomes in patients treated with novel immunoconjugate therapies.
  • To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  • To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.

WP2 - Task 2 -Immunological analyses

Other

Objectives

  • evaluate the association between levels and subtypes of T cells in PB before and after ADCs with COs.
  • Analyze the expression of PD1, CD25, 41BB/CD137, CTLA4, CD28, and other T cell co-stimulatory molecules, and correlate them with COs.
  • Evaluate the expansion of NK cells along with their markers of activation, exhaustion, maturation, chemotaxis.
  • evaluate the association between T cell exhaustion with treatment failure.
  • evaluate the association between T cell exhaustion with previous lines of treatment or other clinical factors such as relapsed time.
  • evaluate the association between T cell clusters with the development of cytopenia during treatment.
  • investigate whether immunosenescence and inflammaging can predict response and clinical outcomes in elderly patients (≧ 70) undergoing treatment with ADCs.
  • Immunological characterization of T cell subset by bulk RNAseq before and after ADCs with clinical outcomes.

WP2 - Task 3 - Tumor tissue analyses

Other

Objectives

  • characterize intratumoral immune effector cell distribution and assess T-cell functional fitness and exhaustion states within tumor-draining lymphnodes using DSP.
  • investigate correlation between ADCs surface target antigens expression level and response to ADCs treatment
  • investigate MYC translocation alone or in association with BCL2 and or BCL6 translocation or other MYC chromosomal aberrations as predictive factors of response to ADCs assessed by FISH on diagnostic biopsy and last biopsy preADCs treatment.
  • investigate TP53 mutation and del17p as predictive factor of response to ADCs.
  • investigate mutations and CNVs as predictive factors of response to ADCs treatment.
  • investigate ADCs target antigens RNA expression level and correlation with response to ADCs treatment.
  • characterize transcriptomic and sRNA landscapes to identify gene expression signatures and microRNA profiles associated with response to ADCs treatment.

WP2 - Task 4 - Imaging analyses

Other

Objectives

  • explore how tumor metabolic activity signature predict prognosis and treatment response during ADCs-approved treatments.
  • explore how tumor heterogeneity activity predicts prognosis and treatment response during ADCs-approved treatments.
  • explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during ADCs-approved treatments.
  • explore novel prognostic markers of progression in CT scans and PET scans.
  • apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT scans, aiming to enhance prediction of prognosis and treatment response in patients undergoing ADCs-approved treatments.
  • develop and validate AI-driven multimodal integration frameworks that combine imaging data (PET/CT) with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under ADCs therapy.

WP2 - Task 5 - Microbiome and metabolomics analyses

Other

Objectives

  • To describe plasma and tissue microbiome and metabolomics composition during ADCs-treatments.
  • To investigate whether microbiome/metabolomics predicts outcomes during ADCs-approved treatments.
  • To investigate whether microbiome/metabolomics predicts treatment toxicity during ADCs-approved treatments.

WP3 - Task 1 - Liquid analyses

Other

Objectives

  • To identify and validate biological and molecular biomarkers (i.e. ctDNA/MRD) that predict patient outcomes in patients treated with novel naked antibodies.
  • To evaluate the potential role of clonal hematopoiesis (CH) in terms of therapy-related toxicities and treatment response.
  • To evaluate the potential prognostic role of germline single-nucleotide polymorphisms (SNPs) involved in drug metabolic pathways and cell-to-cell interactions.

WP3 - Task 2 - Immunological analyses

Other

Objective

  • Evaluate the expansion of immunological cells along with their markers of activation, exhaustion, maturation, and chemotaxis.

WP3 - Task 3 - Tumor tissue analyses

Other

Objectives

  • To investigate the correlation between naked antibodies surface target antigens (e.g. CD19) expression level and response to naked antibodies.
  • To investigate MYC translocation alone or in association with BCL2 and or BCL6 translocation, or other MYC chromosomal aberrations as predictive factors of response to naked antibodies (assessed by FISH on diagnostic biopsy and last biopsy pre- naked antibodies).
  • To investigate TP53 mutation and del17p as predictive factor of response to naked antibodies.
  • To investigate mutations and copy number variations (CNVs) (either studied by targeted sequencing or by WES) as predictive factors of response to treatment.

WP3 - Task 4 - Imaging analyses

Other

Objectives

  • explore how tumor metabolic activity signature predict prognosis and treatment response during naked Abs-approved treatments.
  • explore how tumor heterogeneity activity predicts prognosis and treatment response during naked Abs-approved treatments.
  • explore how PET findings are integrated with other biomarkers, we refine predictions of prognosis and treatment efficacy during naked Abs-approved treatments.
  • explore novel prognostic markers of PD in CT and PET scans.
  • apply advanced artificial intelligence methods (radiomics and deep learning) for automated extraction of complex imaging features from PET/CT, aiming to enhance prediction of prognosis and treatment response in patients undergoing naked Abs-approved treatments.
  • develop and validate AI-driven multimodal integration frameworks that combine imaging data with clinical and molecular biomarkers, refining risk stratification and enabling early detection of progression under naked Abs therapy.

WP3 - Task 5 - Microbiome and metabolomics analyses

Other

Objectives

  • To describe plasma and tissue microbiome and metabolomics composition during naked antibodies -approved treatments.
  • To investigate whether microbiome/metabolomics predicts outcomes during naked antibodies -approved treatments.
  • To investigate whether microbiome/metabolomics predicts treatment toxicity during naked antibodies -approved treatment.

Primary outcomes

  1. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and Progression Free Survival (PFS).

  2. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and Overall Survival (OS).

  3. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between between MRD status and clinical response.

  4. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Comparison between MRD negativity rates obtained by different BsAbs time to obtain MRD negativity by different BsAbs.

  5. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation between baseline ctDNA levels and outcome (response, PFS, OS).

  6. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).

  7. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between baseline ctDNA and MRD with imaging biomarkers (Total Metabolic Tumor Value (TMTV), Maximum Tumor Dissemination (Dmax), Standardized Uptake Value maximum (SUVmax), Artificial Intelligence (AI) features etc).

  8. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of CH with PFS, OS and therapy-related toxicities.

  9. T-cell engager antibodies - Work package (WP 1) -Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of SNPs with PFS, OS and therapy-related toxicities.

  10. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Quantification of CD4+ and CD8+T lymphocyte clusters and soluble mediators of inflammagin, at baseline, month +3 (M3) and End Of Treatment (EOT), and correlation with clinical outcome (PFS, OS).

  11. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Measuring NK cells count at baseline and M3 and correlation with outcome.

  12. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between CD4+ Treg, CD4+, and CD8+ T lymphocyte counts at M3 and Complete Metabolic Response (CMR)/MRD-.

  13. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between CD4+ Treg, CD4+, and CD8+ T Lymphocyte counts at M3 and 2-Y PFS.

  14. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Expression of co-stimulatory molecules such as PD1, CD25, 41BB/CD137, CTLA4, and CD28 on T cells at M3 and their correlation with achieving a CMR.

  15. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation between T cell exhaustion and treatment failure.

  16. T-cell engager antibodies - Work package (WP 1) - Task 2 -Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation of T lymphocyte clusters and soluble mediators of inflammaging with safety (e.g. Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), infections).

  17. T-cell engager antibodies - Work package (WP 1) - Task 3 - Tumor tissue analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation of specific mutational profiles with Overall Response Rate (ORR) rates, 2-Y PFS and 2-Y OS.
    • Correlation of specific transcriptomic signatures with ORR rates, 2-Y PFS and 2-Y OS.
    • Correlation of intra-tumoral T-cell populations and non-T-cell populations with ORR rates, 2-Y PFS and 2-Y OS.
    • Identifying specific relapse patterns, with the hypothesis that alterations in tumor genes facilitating immune evasion are enriched in clones emerging at relapse (i.e., secondary resistance).
    • Correlation between target antigen surface level (i.e. CD20) with ORR rates, 2-Y PFS and 2-Y OS.

  18. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and PFS.

  19. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and OS.

  20. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and clinical response.

  21. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Comparison between MRD negativity rates obtained by different BsAbs time to obtain MRD negativity by different BsAbs.

  22. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation between baseline ctDNA levels and outcome (response, PFS, OS).

  23. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).

  24. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between baseline ctDNA and MRD with imaging biomarkers (TMTV, Dmax, SUVmax, AI features etc).

  25. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of CH with PFS, OS and therapy-related toxicities.

  26. Immunoconjugates antibodies - Work package 2 (WP2) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of SNPs with PFS, OS and therapy-related toxicities.

  27. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Quantification of CD4+ and CD8+T lymphocyte clusters and soluble mediators of inflammagin, at baseline, month +3 (M3) and EOT, and correlation with clinical outcome (PFS, OS).

  28. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Measuring NK cells count at baseline and M3 and correlation with outcome.

  29. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between CD4+ Treg, CD4+, and CD8+ T lymphocyte counts at M3 and CMR/MRD-.

  30. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between CD4+ Treg, CD4+, and CD8+ T Lymphocyte counts at M3 and 2-Y PFS.

  31. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Expression of co-stimulatory molecules such as PD1, CD25, 41BB/CD137, CTLA4, and CD28 on T cells at M3 and their correlation with achieving a CMR.

  32. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation between T cell exhaustion and treatment failure.

  33. Immunoconjugates antibodies - Work package 2 (WP2) Task 2 - Immunological analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation of T lymphocyte clusters and soluble mediators of inflammaging with safety (e.g. infections).

  34. Immunoconjugates antibodies - Work package 2 (WP2) Task 3 - Tumor tissue analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between target antigen surface level and CRR with ADCs treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before ADCs treatment.

  35. Immunoconjugates antibodies - Work package 2 (WP2) Task 3 - Tumor tissue analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between target antigen surface level and OS, PFS and ORR with ADCs treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before ADCs treatment and correlation with biological and imaging predictors. Correlation of CH with PFS, OS and therapy-related toxicities and correlation of SNPs with PFS, OS and therapy-related toxicities.

  36. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and PFS.

  37. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and OS.

  38. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and clinical response.

  39. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Comparison between MRD negativity rates obtained by different naked antibodies time to obtain MRD negativity by different naked antibodies.

  40. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Correlation between baseline ctDNA levels and outcome (response, PFS, OS).

  41. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between MRD status and other clinical and biological prognostic markers (e.g. mutational patterns, T-cell phenotypes).

  42. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between baseline ctDNA and MRD with imaging biomarkers (TMTV, Dmax, SUVmax, AI features etc).

  43. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of CH with PFS, OS and therapy-related toxicities.

  44. Naked antibodies - Work package 3 (WP3) Task 1 - Liquid analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association of SNPs with PFS, OS and therapy-related toxicities.

  45. Naked antibodies - Work package 3 (WP3) Task 3 - Tumor tissue analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between target antigen surface level and CRR with naked antibodies-based treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before naked antibodies-based therapies.

  46. Naked antibodies - Work package 3 (WP3) Task 3 - Tumor tissue analyses

    Time frame: from enrollment start to final analyses (15 years)

    • Association between target antigen surface level and OS, PFS and ORR with naked antibodies based-treatment, assessed in immunohistochemistry (IHC) on diagnosis or last relapse biopsy before naked antibodies based-treatment and correlation with biological and imaging predictors. Correlation of CH with PFS, OS and therapy-related toxicities and correlation of SNPs with PFS, OS and therapy-related toxicities.

  47. All Work packages

    Time frame: from enrollment start to final analyses (15 years)

    • Prognostic quantitative PET indices: Metabolic Tumor Volume (MTV), Total Glycolytic Volumes (TLG), SUVmax and SUVpeak, other index of tumor dissemination (maximum distance between the lesion, product of distance and MTV, etc.…) and radiomics index.

  48. All Work packages

    Time frame: from enrollment start to final analyses (15 years)

    • Association between plasma and lymph nodes microbiome and outcomes (ORR, Complete Response Rate (CRR), PFS, OS) in NMAB-approved treatments.

  49. All Work packages

    Time frame: from enrollment start to final analyses (15 years)

    • Evaluation of correlations between immune cell subsets (T-cell subsets, NK cells), immunological clusters, soluble mediators, and clinical efficacy.

Study contacts

Contact information is provided by the study sponsor or research team.

Uffici Studi FIL

CONTACT

[email protected]

+390131033169

Uffici Studi FIL

CONTACT

[email protected]

+390599769910

Sponsors and collaborators

Lead sponsor

Fondazione Italiana Linfomi - ETS

Other

Registry information

Official study title

Multilayer Biological Analysis of Novel Monoclonal Antibodies (MABs) in B-Cell Non-Hodgkin Lymphoma (NHL): A Translational and Prospective Observational Study Within Italian Clinical Practice (BIO-FIL_MAB Trial)

Acronym: BIO-FIL_MAB

Important dates

Study start
2026
Primary completion
2041
Study completion
2041
First posted
Aug 17, 2026
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.